Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females, with over 1.2 million new cases and 608,700 deaths estimated in every year[@b1]. The development of CRC has been demonstrated as a complex process caused by many factors, such as environmental and genetic mutation[@b2]. Many studies indicated that DNA damage was significantly associated with cancer development, which caused errors during DNA synthesis. Besides, it has reported that the DNA repair capacity was related to the inherited factors. Therefore, individuals with inherited impairment in DNA repair capacity are often associated with increased risk of cancers[@b3].

Emerging evidence have demonstrated that the DNA damage repair can be activated by various pathways, including nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR), double-strand break repair (DSBR), and direct repair (DR). Among these, the NER is mainly responsible for repairing bulky DNA damage, such as DNA adducts caused by UV radiation, mutagenic chemicals and chemotherapeutic drugs[@b4]. Besides, many key NER genes, such as *ERCC1, XPA, XPB/ERCC3, XPC, XPD/ERCC2, XPE/DDB1, XPF/ERCC4,* and *XPG/ERCC5*, have been identified, which play vital roles in DNA damage repairing and maintaining genome integrity.

*Xeroderma Pigmentosum complementation group G* (*XPG*), also named *ERCC5*, is located on chromosome 13q22-q33, consisting of 15 exons and 14 introns[@b5]. *XPG* is a member of the flap structure-specific endonuclease 1 (FEN1) family and encodes a protein of 1186 amino acids. It has reported that a defective *XPG* plays a pivotal role in the initiation of carcinogenesis and leads to DNA repair defects, genomic instability, and failure of gene transcription modulation[@b6][@b7][@b8]. To date, at least six single-nucleotide polymorphisms (SNPs) in *XPG* gene have been identified, and the common Asp1104His polymorphism (rs17655 G/C, minor allele frequency \> = 0.444, CHB in HapMap), regarded as a tagSNP, was widely investigated for its relationship to the risk of different cancers[@b9]. Recently, some studies have reported that Asp1104His polymorphisms in *XPG* were associated with risk of CRC; but, the results remained inconsistent. Thus, we genotyped the *XPG* Asp1104His polymorphism and evaluated its association with CRC susceptibility in an independent Chinese population.

Results
=======

Study Characteristics
---------------------

A total of 878 CRC cases and 884 healthy controls were recruited in our analysis, and the characteristics are summarized in [Table 1](#t1){ref-type="table"}. Except that more individuals with family history of cancer were in cases than that in controls (23.5% in CRC cases; 9.8% in controls, *P* \< 0.001), there were no significant difference in distributions of age, sex, smoking status and drinking status (*P* = 0.632, 0.125, 0.187 and 0.222, respectively). Among the CRCs, 52.3% of patients suffered from colon cancer, and 47.7% from rectum cancer. Moreover, 7.1%, 77.1%, and 15.8% of cases were classified as poor, moderate and well differentiation grade, respectively. The Dukes A, B, C, and D stages were 7.0%, 44.6%, 36.6%, and 11.8%, respectively. The genotype distributions of the *XPG* polymorphism between the cases and controls are listed in [Table 2](#t2){ref-type="table"}. The genotype frequencies of *XPG* Asp1104His polymorphism were 32.6% (Asp/Asp), 52.3% (Asp/His) and 15.1% (His/His) in the cases, which were significantly different from those in the controls (40.2%, 45.8%, 14.0%). Besides, the *XPG* C (His) allele frequency was 52.6% among the cases, while 47.4% among the controls, indicating a significantly statistically difference (*P* = 0.008). The observed genotype frequencies among the controls were in agreement with the HWE (*P* = 0.622). Furthermore, the MAF of *XPG* Asp1104His is 0.369 in the controls, which was about the same as that in HapMap-CHB database (<http://www.ncbi.nlm.nih.gov>).

Effects in association between *XPG* Asp1104His and CRC risk
------------------------------------------------------------

We adjusted age, sex, smoking status, and drinking status for multivariate logistic regression analysis, revealing that the individuals with the His/His or Asp/His had a significantly increased risk of CRC (His/His vs Asp/Asp, adjusted OR = 1.03, 95% CI = 1.06--1.11; Asp/His vs Asp/Asp, adjusted OR = 1.41, 95% CI = 1.15--1.74), compared with the Asp/Asp genotype; besides, the His/His + Asp/His genotypes were related to higher CRC susceptibility (adjusted OR = 1.40, 95% CI = 1.15--1.70). In the stratification analyses on the dominant model, as shown in [Table 3](#t3){ref-type="table"}, the His/His + Asp/His genotypes were associated with an increased risk of CRC in every subgroup except for the female. Moreover, the relationships of *XPG* Asp1104His polymorphism to the clinicopathological characteristics were also evaluated ([Table 4](#t4){ref-type="table"}). The risk effect of His/His + Asp/His genotypes was found in each group of tumor site and Dukes stage (all *P* \< 0.05); however, only in the subgroup of moderately differentiated grade, we identified a significant increased risk (adjusted OR = 1.44, 95% CI = 1.17--1.78), but not in the subgroup of poorly and well differentiated grade (OR = 1.20, CI = 0.70--2.06; OR = 1.27, 95% CI = 0.87--1.85).

The results of meta-analysis
----------------------------

A total of five eligible studies[@b2][@b10][@b11][@b12], including 2649 cases and 2848 controls were recruited for meta-analysis ([Table S1](#s1){ref-type="supplementary-material"}). We observed a significant association between *XPG* Asp1104His polymorphism and CRC risk under homozygote comparison (His/His vs. Asp/Asp: OR = 1.24; 95% CI: 1.03--1.47; *P* = 0.02; [Figure 1a](#f1){ref-type="fig"}), and dominant model (His/His + Asp/His vs. Asp/Asp: OR = 1.35; 95% CI: 1.20--1.51; *P* \< 0.001; [Figure 1b](#f1){ref-type="fig"}). When stratified by ethnicity, an evidently increased risk was identified in the Asian populations: His/His vs. Asp/Asp: OR = 1.28; 95% CI: 1.05--1.55; *P* = 0.012 ([Figure S1a](#s1){ref-type="supplementary-material"}); Asp/His vs. Asp/Asp: OR = 1.49; 95%CI:1.29--1.73; *P* \< 0.001 ([Figure S1b](#s1){ref-type="supplementary-material"}); His/His + Asp/His vs. Asp/Asp: OR = 1.44; 95% CI: 1.25--1.65; *P* \< 0.001 ([Figure S1c](#s1){ref-type="supplementary-material"}). No heterogeneities were observed in our meta-analysis (all *P* \> 0.1; [Table 5](#t5){ref-type="table"}). We used the Begg\'s rank correlation method and Egger\'s weighted regression method to assess publication bias. Fortunately, there was no obvious publication bias in this meta-analysis (His/His vs. Asp/Asp: Begg\'s test *P* = 0.327, Egger\'s test *P* = 0.326, t = −1.17, 95% CI = −3.020--1.394; His/His + Asp/His vs. Asp/Asp: Begg\'s test *P* = 0.142, Egger\'s test *P* = 0.139, t = −2.01, 95% CI = −4.394--0.997) ([Figure 2](#f2){ref-type="fig"}).

Discussion
==========

In the NER pathway, XPG cleaves the damaged DNA 3′ to the damaged site, nonenzymatically participates in the 5′ incision and stabilizes the DNA repair complex to the damaged DNA[@b13]. The SNPs in the coding region of the *EECC5/XPG* gene may result in a subtle alteration of the ERCC5/XPG activity and modulation of cancer susceptibility[@b14]. Berhane N et al. indicated that an amino acid changing from an acidic aspartic acid residue to a basic histidine residue could affect the protein structure of XPG, and thus influence the protein--protein interactions and the stability of the preincision complex XPG C-terminus[@b15]. To date, it has been proven that *XPG* SNPs were associated with some cancers, such as lung cancer[@b16] and breast cancer[@b17]. These implied a certain link between the *XPG* polymorphisms and the development of certain cancers.

The association between CRC and *XPG* Asp1104His polymorphism has been widely studied[@b2][@b10][@b18]. Liu et al. have suggested that the *XPG* Asp1104His polymorphism contributed to the increased risk for CRC and also was associated with shorter PFS for the CRC patients receiving oxaliplatin-based chemotherapy[@b10]. However, Mort R et al. reported that *XPG* Asp1104His were not associated with CRC risk[@b19]. In addition, no previous studies examined the association between the *XPG* Asp1104His SNP and the risk of CRC with demographic characteristics and clinic pathological parameters. Thus, we conducted a hospital-based case-control study and meta-analysis to comprehensively evaluate the association of the Asp1104His polymorphisms with CRC.

In this study, we investigated the association between the *XPG* Asp1104His and CRC susceptibility. Our findings showed a significant increased frequency of the variant allele in cases (C-allele 0.526) compared to controls (C-allele 0.474). We found that the *XPG* Asp1104His was related to an increased the risk of CRC in codominant and dominant model, as Liu et al.[@b9] reported. In subgroup analysis, the male in the dominant model of *XPG* Asp1104His seemed to be more susceptible to CRC, but not the female ([Table 3](#t3){ref-type="table"}). The reason might be that women have relatively healthy living habits and particular physiological mechanisms, which protect them from CRC. Furthermore, in the subgroup of clinicopathology characteristics, we observed that the Asp/His+His/His genotype were associated with a significantly increased risk of intermediate grade CRC, but not the low and high grade CRC. This phenomenon may be due to the relatively small number of patients with low and high grade CRC; and in the subgroups of tumor location and tumor stage, the associations remained still. These results suggested that *XPG* Asp1104His polymorphism could help to diagnose CRC. As the cancer stage was correlated to prognosis, we inferred that the *XPG* Asp1104His polymorphism did not predict the progression of CRC based on our results.

Furthermore, our meta-analysis revealed that individuals with His/His and His/His+Asp/His genotype were more likely to susceptible to CRC, which was similar to the result of our study. In the subgroup of ethnicity, we found that the *XPG* His/His and Asp/His genotypes seemed to be more susceptible to CRC in Asians, but not in European. This might be account for ethnic differences and diverse live environment. In addition, it was also likely that the observed ethnic differences may be due to chance because studies with small sample size may have insufficient statistical power to detect a slight effect[@b20].

Some limitations should be noted when interpreting our findings. Firstly, many exposure variables were not taken into account, such as diet in general, history of other cancer and chronic diseases, which may affect the reliability of the results. Thus, more comprehensive studies are needed to validate these findings. Secondly, the sample sizes in our case-control study and meta-analysis study both are relatively small and might not provide sufficient power to assess the association between *XPG* Asp1104His polymorphism and CRC risk. Thirdly, our study population only included the Chinese; studies with ethnically diverse populations are warranted.

In conclusion, our study showed that the *XPG* Asp1104His polymorphism appeared to confer susceptibility to CRC. Further well-designed studies with larger sample sizes will be needed to confirm the impact of *XPG* Asp1104His polymorphism on CRC susceptibility.

Methods
=======

Ethics statement
----------------

The study was approved by the institutional review board of the First Affiliated Hospital of Nanjing Medical University. The informed written consent was obtained from all subjects. In addition, the methods were carried out in accordance with the approved guidelines. And, all experimental protocol was approved by the institutional review board of the First Affiliated Hospital of Nanjing Medical University.

Study population
----------------

We recruited CRC (CRC) cases and healthy controls from September 2010 to October 2013. Patients without restriction on age and sex were consecutively recruited at The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. All of the cases were pathologically or histologically confirmed. The pathological stage of CRC at the time of diagnosis was classified into Dukes A, B, C, and D. Tumor grade was classified into well differentiated, moderately differentiated and poorly differentiated. Controls were randomly selected from a healthy screening campaign in the same region. The selection criteria for controls included cancer-free individuals and frequency matched to cases for sex and age. All of the participants were interviewed with a self-administered questionnaire after obtaining a written informed consent. After interview, about 5 ml of venous blood sample was collected from each subject.

Genotyping
----------

Genomic DNA isolated from 5 ml whole blood was used to genotype *XPG* Asp1104His by using the TaqMan assay (Applied Biosystems). The sequences of primer and probe for each SNP are available on request. Genomic DNA of 50 ng and 0.56 mix (TaKaRa Bio, JPN) was used for each reaction and amplification was performed under the following conditions: 50°C for 2 min, 95°C for 10 min followed by 45 cycles of 95°C for 15 sec, and 60°C for 1 min. We assessed genotype data quality by typing 10% blinded replicate samples and the concordance rate was 100.0%.

Statistical analysis
--------------------

For the case-control study, the Hardy--Weinberg equilibrium (HWE) for genotype distribution in controls was tested by a goodness-of-fit *x^2^* test. Crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate association between the genotypes and risk of CRC according to the significant genetic models by univariate and multivariate unconditional logistic regression models, respectively. *P* \<0.05 was considered as statistically significant, and all statistical tests were two sided. Statistical analyses were done using SAS 9.1.3 (SAS Institute, Cary, NC).

Meta-analysis
-------------

### Eligibility of relevant studies

To further confirm the relationship between *XPG* Asp1104His polymorphism and CRC, we carried out a meta-analysis. The PubMed database was searched with terms "*XPG*", "ERCC5", "viceversa Xeroderma Pigmentosum group G", "excision repair cross-complementing group 5″, "polymorphism", "colorectal cancer", as well as their combinations for all genetic studies on the relationship between *XPG* polymorphism and CRC risk up to March 2014. We also searched references in published articles and reviews on this topic in PubMed. Eligible studies had to meet the following criteria: (a) only case-control design; (b) studies exploring the correlation between CRC and *XPG* Asp1104His polymorphism. A total of 5 potential relevant studies (including our study) were retrieved through PubMed[@b2][@b10][@b11][@b12].

### Data extraction

Two investigators find the publications on the topic and then a selection of the detected studies independently according to the inclusion criteria listed above. Then, the following information was collected from each study: first author\'s name, year of publication, study design, ethnicity and numbers of cases and controls with the *XPG* Asp1104His genotypes, respectively ([Table S1](#s1){ref-type="supplementary-material"}).

### Statistical analysis

The chi-square based Q-test was used to evaluate the heterogeneity. The pooled OR was assessed in the fixed-effects model by Mantel--Haenszel method when *P* \>0.05. Otherwise, the random-effects model by DerSimonian and Laird method was used[@b21]. The modified Egger\'s linear regression test was used to detect the potential publication bias. Crude ORs and 95% CIs were used to assess the intensity of the correlation between *XPG* Asp1104His polymorphism and CRC risk. The pooled ORs were evaluated on co-dominant model (His/Asp *vs.* Asp/Asp, His/His *vs.* Asp/Asp), dominant model (His/His + Asp/His *vs.* Asp/Asp, recessive model (His/His *vs.* Asp/His + Asp/Asp) and allele (His *vs*. Asp), respectively. Statistical analyses were used by STATA version 11.0 (Stata Corporation, College Station, TX, USA).
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###### Distribution of selected variables between colorectal cancer cases and controls

                                Cases (n = 878)     Controls (n = 884)                  
  -------------------------- ------------------- ---------------------- ------- ------- ---------
  Age (mean+SD)                  60.0 ± 12.9          60.3 ± 13.7        0.632          
  Sex                                                                                     0.125
   Male                              541                  61.6            513    58.0        
   Female                            337                  38.4            371    42.0        
  Smoking status                                                                 0.187  
   Never                             580                  66.1            610    69.0        
   Ever                              298                  33.9            274    31.0        
  Drinking status                                                                0.222  
   Never                             636                  72.4            663    75.0        
   Ever                              242                  27.6            221    25.0        
  Family history of cancer                                                               \<0.001
   No                                672                  76.5            797    90.2        
   Yes                               206                  23.5            87      9.8        
  Tumor site                                                                                 
   Colon                             459                  52.3                               
   Rectum                            419                  47.7                               
  Tumor grade                                                                           
   Low                               62                   7.1                                
   Intermediate                      677                  77.1                               
   High                              139                  15.8                               
  Dukes stage                                                                           
   A                                 61                   7.0                                
   B                                 392                  44.6                               
   C                                 321                  36.6                               
   D                                 104                  11.8                               

SD: standard deviation.

###### Distribution of genotypes of *XPG* Asp1104His and their associations with risk of colorectal cancer

  Gentypes            Cases(n = 878) n/%   controls(n = 884) n/%   Crude OR(95%CI)   Adjusted OR(95%CI)[\*](#t2-fn1){ref-type="fn"}         *P*                            
  ------------------ -------------------- ----------------------- ----------------- ------------------------------------------------ ------------------ ------------------ ---------
  Asp/Asp                    286                   32.6                  355                              40.2                        1.00(reference)    1.00(reference)        
  Asp/His                    459                   52.3                  405                              45.8                        1.41(1.15--1.73)   1.41(1.15--1.74)    0.001
  His/His                    133                   15.1                  124                              14.0                        1.33(1.00--1.78)   1.34(1.00--1.79)    0.048
  His/His +Asp/His           592                   67.4                  529                              59.8                        1.39(1.14--1.69)   1.40(1.15--1.70)   \<0.001
  His allele                 725                   52.6                  653                              47.4                        1.20(1.05--1.37)                       0.008

\*Adjusted for age, sex, and smoking and drinking status in logistic regression model.

###### Association between *XPG* Asp1104His Genotypes and demographic characteristics

                                Genotypes                                                                  
  -------------------------- ------------- ----------- --------- ----------- --------- ------------------- -------
  Total                         286/355     32.6/40.2   592/529   67.4/59.8   \<0.001   1.40 (1.15--1.70)      
  Age                                                                                                          
   ≤60                          142/172     32.3/42.9   298/229   67.7/57.1    0.002    1.57 (1.18--2.09)      
   \>60                         144/183     32.9/37.9   294/300   67.1/62.1    0.05     1.31 (1.00--1.74)      
  Sex                                                                                                          
   Male                         178/218     32.9/42.5   363/295   67.1/57.5    0.001    1.52 (1.18--1.96)      
   Female                       108/137     32.1/37.0   229/234   67.9/63.0    0.111    1.30 (0.94--1.79)      
  Smoking status                                                                                               
   Never                        194/237     33.5/38.9   386/378   66.5/61.1    0.041    1.28 (1.01--1.63)   0.172
   Ever                         92/118      30.9/43.1   206/156   69.1/56.9    0.002    1.72 (1.21--2.43)      
  Drinking status                                                                                              
   Never                        209/260     32.9/39.2   427/403   67.1/60.8    0.014    1.33 (1.06--1.68)   0.367
   Ever                          77/95      31.8/43.0   165/126   68.2/57.0    0.016    1.62 (1.10--2.40)      
  family history of cancer                                                                                     
   No                           222/316     33.0/39.7   450/481   67.0/60.3    0.007    1.35 (1.09--1.67)   0.330
   Yes                           39/64      31.1/44.8   142/48    68.9/55.2    0.028    1.81 (1.07--3.07)      

CI confidence interval, OR odds ratio.

\*Adjusted for age, sex, smoking, and drinking status in logistic regression model.

###### Association between *XPG* Asp1104His Genotypes and Clinical Characteristics of Colorectal Cancer

                       Asp/Asp    His/His+Asp/His                                               
  ------------------- ---------- ----------------- ------------------- ------------------- ---------
  Controls(n = 884)    355/40.2      529/59.8       1.00 (reference)    1.00 (reference)        
  Cases(n = 878)       286/32.6      592/67.4       1.39 (1.14--1.69)   1.40 (1.15--1.70)   \<0.001
  Tumor site                                                                                    
   Colon               144/31.4      315/68.6       1.47 (1.16--1.86)   1.48 (1.16--1.87)    0.001
   Rectum              142/33.9      277/66.1       1.31 (1.03--1.67)   1.32 (1.03--1.69)    0.026
  Tumor grade                                                                                   
   Low                 22/35.5        40/64.5       1.22 (0.71--2.09)   1.20 (0.70--2.06)    0.507
   Intermediate        216/31.9      461/68.1       1.43 (1.16--1.77)   1.44 (1.17--1.78)   \<0.001
   High                48/34.5        91/65.5       1.27 (0.88--1.85)   1.27 (0.87--1.85)    0.216
  Dukes stage                                                                                   
   A+B                 144/31.8      309/68.2       1.44 (1.13--1.83)   1.15 (1.14--1.84)    0.002
   C+D                 142/33.4      283/66.6       1.34 (1.05--1.70)   1.35 (1.06--1.72)    0.017

\*Adjusted for age, sex, smoking, and drinking status in logistic regression model.

###### Meta-analysis of the association between the *XPG* Asp1104His polymorphism and colorectal cancer risk

                            His/His vs. Asp/Asp    Asp/His vs. Asp/Asp    His/His + Asp/His vs. Asp/Asp    His/His vs. Asp/His + Asp/Asp                                                     
  ----------- ----------- ---------------------- ---------------------- -------------------------------- -------------------------------- ----------------- ------------- ------------------ -------------
  Total        2649/2848     1.24(1.03--1.47)         0.020/0.562               0.85(0.69--1.05)                   0.127/0.303             1.35(1.20--1.5)     0/0.473     0.97(0.83--1.14)   0.750/0.430
  Ethnicity                                                                                                                                                                                         
  Asian        1906/1969     1.28(1.05,1.55)          0.012/0.473               1.49(1.29,1.73)                      0/0.418               1.44(1.25,1.65)     0/0.636     0.98(0.83,1.16)    0.285/0.797
  Caucasian     743/879      0.97(0.59,1.58)          0.900/0.372               1.19(0.96,1.48)                    0.109/0.397             1.16(0.94,1.44)   0.147/0.718   0.92(0.57,1.48)    0.720/0.262

[^1]: These three authors contributed equally to this work.
